Sustainable and Efficient Platform of New Therapeutic Development for Early Breast Cancer (S-FACT)
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Carboplatin (Primary) ; Niraparib (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Breast cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms S-FACT
Most Recent Events
- 08 Aug 2024 New trial record